Teiko Bio Expands Blood Specimen Stabilization Services to Australia, Leveraging TokuKit Technology

Teiko Bio, a company co-founded by Ramji Srinivasan, has announced the expansion of its blood specimen stabilization services to Australia, offering its proprietary TokuKit technology for clinical trials. The announcement, made by Srinivasan on social media, highlighted the company's capability to stabilize blood specimens collected within Australia. This move aims to enhance the integrity and reliability of clinical trial data by addressing challenges in sample transportation and preservation.

"Also, if you need blood specimens stabilized if collected in Australia, we got you," stated Ramji Srinivasan, co-founder of Teiko Bio, in a recent tweet.

The core of this offering is the TokuKit, a three-step, centrifuge-free preservation system designed to stabilize immune cell populations and functional marker subsets in whole blood for extended periods. This technology allows for on-site fixation of blood samples at clinical sites, significantly reducing the impact of temperature fluctuations and transit delays that can compromise sample quality. Teiko Bio's website indicates that the TokuKit can preserve samples for months, even up to 24 months at -80°C.

Teiko Bio's services, including the TokuKit, are utilized across global clinical trial sites in the US, EU, and Australia. The company emphasizes that its method simplifies the process of blood collection and preservation, making it faster, easier, and more cost-effective than traditional PBMC isolation. This approach is crucial for maintaining the integrity of immune cell readouts, which are vital for accurate clinical trial data.

Ramji Srinivasan, a seasoned entrepreneur, co-founded Teiko Bio with a mission to make immune profiling a reality for clinical trials and eventually for patients. His previous venture, Counsyl, was acquired by Myriad Genetics. Teiko Bio's focus on high-dimensional cytometry and robust sample stabilization aims to overcome common hurdles in clinical research, such as the high failure rate of blood samples due to improper handling. The expansion into Australia underscores Teiko Bio's commitment to supporting global clinical trials with reliable and advanced sample management solutions.